EORTC-ROG expert opinion: Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach

Radiotherapy and Oncology

Volumn 92, Issue 2, 2009, Pages 164-175

  Matzinger, Oscar ^a,b   Gerber, Erich ^c   Bernstein, Zvi ^d   Maingon, Philippe ^e   Haustermans, Karin ^f   Bosset, Jean François ^g   Gulyban, Akos ^a   Poortmans, Philip ^a   Collette, Laurence ^a   Kuten, Abraham ^d  

^a EORTC DATA CENTER   (Belgium)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Oncology Department ^*

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

Author keywords

Gastric; Gastroesophageal; Guideline; Neoadjuvant; Radiotherapy; Target volume

Indexed keywords

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CONSENSUS; DOSIMETRY; DRUG DELIVERY SYSTEM; HEALTH CARE ORGANIZATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MEDLINE; PRACTICE GUIDELINE; PREOPERATIVE RADIOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; STOMACH; TREATMENT PLANNING;

ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOADJUVANT THERAPY; PRACTICE GUIDELINES AS TOPIC; STOMACH NEOPLASMS;

EID: 67651119941     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.03.018     Document Type: Article

References (68)

1. Keeney S., and Bauer T.L. Epidemiology of adenocarcinoma of the esophagogastric junction. Surg Oncol Clin N Am 15 (2006) 687-696
2. Moehler M., Lyros O., Gockel I., Galle P.R., and Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 14 (2008) 3773-3780
3. Maehara Y., Hasuda S., Koga T., Tokunaga E., Kakeji Y., and Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87 (2000) 353-357
4. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 (2008) 453-462
5. Yoo C.H., Noh S.H., Shin D.W., Choi S.H., and Min J.S. Recurrence following curative resection for gastric carcinoma. Br J Surg 87 (2000) 236-242
6. de Manzoni G., Pedrazzani C., Pasini F., et al. Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol 29 (2003) 506-510
7. Van Cutsem E., Van de Velde C., Roth A., et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44 (2008) 182-194
8. Crehange G., Bonnetain F., Chauffert B., Rat P., Bedenne L., and Maingon P. Resectable adenocarcinoma of the oesophagogastric junction care: Which perioperative treatment?. Cancer Radiother 12 (2008) 365-373
9. Yuasa N., Miyake H., Yamada T., Ebata T., Nimura Y., and Hattori T. Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction. World J Surg 30 (2006) 364-371
10. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
11. Stein H.J., Feith M., and Siewert J.R. Cancer of the esophagogastric junction. Surg Oncol 9 (2000) 35-41
12. Rüdiger Siewert J., Feith M., Werner M., and Stein H.J. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232 (2000) 353-361
13. Feith M., Stein H.J., and Siewert J.R. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 15 (2006) 751-764
14. de Manzoni G., Morgagni P., Roviello F., et al. Nodal abdominal spread in adenocarcinoma of the cardia. Results of a multicenter prospective study. Gastric Cancer 1 (1998) 146-151
15. Dresner S.M., Lamb P.J., Bennett M.K., Hayes N., and Griffin S.M. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 129 (2001) 103-109
16. Carneiro F., and Chaves P. Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction. Surg Oncol Clin N Am 15 (2006) 697-714
17. Xiong H.Q., Gunderson L.L., Yao J., and Ajani J.A. Chemoradiation for resectable gastric cancer. Lancet Oncol 4 (2003) 498-505
18. Tormo Ferrero V., Andreu Martinez F.J., Cardenal Macia R., and Pomares Arias A. Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. Clin Transl Oncol 8 (2006) 611-615
19. Yao J.C., Mansfield P.F., Pisters P.W., et al. Combined-modality therapy for gastric cancer. Semin Surg Oncol 21 (2003) 223-227
20. ICRU. ICRU Report 62: Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50); 1999.
21. Dieleman E.M., Senan S., Vincent A., Lagerwaard F.J., Slotman B.J., and van Sörnsen de Koste J.R. Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 67 (2007) 775-780
22. Pan C.C., Kashani R., Hayman J.A., Kessler M.L., and Balter J.M. Intra- and inter-fraction esophagus motion in 3D-conformal radiotherapy: Implications for ICRU 62 definitions of internal target volume and planning organ at risk volume. Int J Radiat Oncol Biol Phys 60 (2004) 580-581
23. Zhao K.L., Liao Z., Bucci M.K., et al. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol 84 (2007) 283-289
24. Yaremko B.P., Guerrero T.M., McAleer M.F., et al. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 70 (2008) 145-153
25. Burmeister B.H., Walpole E.T., D'Arcy N., et al. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. Invest New Drugs (2008)
26. O'Connor B.M., Chadha M.K., Pande A., et al. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J 13 (2007) 119-124
27. Sastre J., Alfonso R., Macías J.A., Manrique I., Flores L., and Díaz-Rubio E. 5-Fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line. Anticancer Drugs 14 (2003) 543-547
28. Leichman L., Pendyala L., and Leichman C.G. Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future. Semin Oncol 30 (2003) 11-18
29. Khushalani N.I., Leichman C.G., Proulx G., et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20 (2002) 2844-2850
30. Wang S.L., Liao Z., Vaporciyan A.A., et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64 (2006) 692-699
31. Tucker S.L., Liu H.H., Wang S., et al. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 66 (2006) 754-761
32. Jansen E.P., Boot H., Saunders M.P., et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 69 (2007) 1424-1428
33. Dewit L., Verheij M., Valdés Olmos R.A., and Arisz L. Compensatory renal response after unilateral partial and whole volume high-dose irradiation of the human kidney. Eur J Cancer 29A (1993) 2239-2243
34. Pinotti G., and Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol 13 (2002) 1951-1952
35. Labaye J., Sarret D., Duvic C., et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant 20 (2005) 1275-1276
36. Dawson L.A., Ten Haken R.K., and Lawrence T.S. Partial irradiation of the liver. Semin Radiat Oncol 11 (2001) 240-246
37. de Boer H.C., and Heijmen B.J. ENAL: an extension of the NAL setup correction protocol for effective use of weekly follow-up measurements. Int J Radiat Oncol Biol Phys 67 (2007) 1586-1595
38. van der Heide U.A., Kotte A.N., Dehnad H., Hofman P., Lagenijk J.J., and van Vulpen M. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 82 (2007) 38-45
39. ICRU. ICRU Report 50. Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements, ICRU; 1993.
40. Lightdale C.J., and Kulkarni K.G. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 23 (2005) 4483-4489
41. Pfau P.R., Perlman S.B., Stanko P., et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 65 (2007) 377-384
42. Chen C.H., Yang C.C., and Yeh Y.H. Preoperative staging of gastric cancer by endoscopic ultrasound: the prognostic usefulness of ascites detected by endoscopic ultrasound. J Clin Gastroenterol 35 (2002) 321-327
43. van Baardwijk A., Baumert B.G., Bosmans G., et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32 (2006) 245-260
44. Shrikanthan S., Aydin A., Dhurairaj T., Alavi A., and Zhuang H. Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. Clin Nucl Med 30 (2005) 695-697
45. Vrieze O., Haustermans K., De Wever W., et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 73 (2004) 269-275
46. Whitfield G.A., Jackson A., Moore C., and Price P. Radical chemoradiotherapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction: what planning margins should we use?. Br J Radiol 81 (2008) 921-934
47. Ajani J.A., Jiang Y., Faust J., et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 24 (2006) 353-357
48. Lowy A.M., Feig B.W., Janjan N., et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8 (2001) 519-524
49. Sobin LH, Wittekind C (Eds.) UICC: TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
50. Grenacher L., and Hansmann J. Radiological imaging of the upper gastrointestinal tract. Part II. The stomach. Radiologe 47 (2007) 71-88
51. Chen C.Y., Hsu J.S., Wu D.C., et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. Radiology 242 (2007) 472-482
52. Meier I., Merkel S., Papadopoulos T., Sauer R., Hohenberger W., and Brunner T.B. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition. Int J Radiat Oncol Biol Phys 70 (2008) 1408-1417
53. Hennequin C., Quero L., and Mineur L. Gastriccancer: doses and target volumes. Cancer Radiother 12 (2008) 659-662
54. Ajani J.A., Mansfield P.F., Janjan N., et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22 (2004) 2774-2780
55. Siewert J.R., and Sendler A. The current management of gastric cancer. Adv Surg 33 (1999) 69-93
56. Kodera Y., Yamamura Y., Shimizu Y., et al. Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. J Am Coll Surg 189 (1999) 594-601
57. Kodera Y., Yamamura Y., Shimizu Y., et al. Lymph node status assessment for gastric carcinoma: is the number of metastatic lymph nodes really practical as a parameter for N categories in the TNM classification?. J Surg Oncol 69 (1998) 15-20
58. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Ed. Gastric Cancer 1 (1998) 10-24
59. Kim J.J., Song K.Y., Hur H., Hur J.I., Park S.M., and Park C.H. Lymph node micrometastasis in node negative early gastric cancer. Eur J Surg Oncol 35 (2009) 409-414
60. Maruyama K, Gunvén P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 1989;210:596-602.
61. Adachi Y., Oshiro T., Okuyama T., et al. A simple classification of lymph node level in gastric carcinoma. Am J Surg 169 (1995) 382-385
62. de Aretxabala X., Konishi K., Yonemura Y., et al. Node dissection in gastric cancer. Br J Surg 74 (1987) 770-773
63. Zhang Z.X., Gu X.Z., Yin W.B., Huang G.J., Zhang D.W., and Zhang R.G. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 42 (1998) 929-934
64. Bozzetti F. Total versus subtotal gastrectomy in cancer of the distal stomach: facts and fantasy. Eur J Surg Oncol 18 (1992) 572-579
65. Lorchel F., Dumas J.L., Noël A., Wolf D., Bosset J.F., and Aletti P. Esophageal cancer: determination of internal target volume for conformal radiotherapy. Radiother Oncol 80 (2006) 327-332
66. Watanabe M., Isobe K., Takisima H., et al. Intrafractional gastric motion and interfractional stomach deformity during radiation therapy. Radiother Oncol 87 (2008) 425-431
67. van der Geld Y.G., Senan S., van Sörnsen de Koste J.R., Verbakel W.F., Slotman B.J., and Lagerwaard F.J. A four-dimensional CT-based evaluation of techniques for gastric irradiation. Int J Radiat Oncol Biol Phys 69 (2007) 903-909
68. Gao X.S., Qiao X., Wu F., et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67 (2007) 389-396